Buchelli Ramirez Herminia L, Álvarez Álvarez Celso M, Rodríguez Reguero José J, García Clemente Marta M, Casan Clarà Pere
Pneumology Department.
Respir Care. 2014 May;59(5):e77-80. doi: 10.4187/respcare.02692. Epub 2013 Oct 22.
Pulmonary arterial hypertension and secondary pleural effusion have been reported in association with long-term therapy with the multi-tyrosine kinase inhibitor dasatinib, approved for the treatment of chronic myeloid leukemia. Here, we present the case of a 50-year-old man, diagnosed with chronic myeloid leukemia in August 2003, who developed pulmonary arterial hypertension after > 4 years of treatment with dasatinib. The complete remission of pulmonary arterial hypertension following dasatinib discontinuation suggests an etiological role of the drug in its development, although the administration of sildenafil may have played a therapeutic role.
多酪氨酸激酶抑制剂达沙替尼已被批准用于治疗慢性粒细胞白血病，据报道，长期使用该药物治疗会引发肺动脉高压和继发性胸腔积液。在此，我们报告一例50岁男性患者，他于2003年8月被诊断为慢性粒细胞白血病，在使用达沙替尼治疗4年多后出现了肺动脉高压。停用达沙替尼后肺动脉高压完全缓解，这表明该药物在其发病过程中起到了病因学作用，尽管西地那非的使用可能也起到了治疗作用。
